Eledon Pharmaceuticals Inc
NASDAQ:ELDN
Eledon Pharmaceuticals Inc
Free Cash Flow
Eledon Pharmaceuticals Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eledon Pharmaceuticals Inc
NASDAQ:ELDN
|
Free Cash Flow
-$37.4m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-6%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Free Cash Flow
$17.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
20%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Free Cash Flow
$10.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Free Cash Flow
$10.4B
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Free Cash Flow
-$978m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-5%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Free Cash Flow
$3.5B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
12%
|
CAGR 10-Years
24%
|
|
Eledon Pharmaceuticals Inc
Glance View
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The company is headquartered in Irvine, California and currently employs 12 full-time employees. The company went IPO on 2014-09-17. The firm is focused on developing targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis (ALS). Its lead compound in development is AT-1501, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand (CD40L, also called CD154). AT-1501 is engineered to improve both safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. Blocking CD40L inhibits both CD40 and CD11 costimulatory signaling pathways with the potential for better efficacy. The company is focused on developing AT-1501 in up to four indications: ALS, prevention of kidney allograft rejection, prevention of islet cell allograft rejection, and IgA Nephropathy (IgAN). The company has completed a Phase Ia/Ib single ascending dose trial in volunteers and people with amyotrophic lateral sclerosis (ALS).
See Also
What is Eledon Pharmaceuticals Inc's Free Cash Flow?
Free Cash Flow
-37.4m
USD
Based on the financial report for Sep 30, 2024, Eledon Pharmaceuticals Inc's Free Cash Flow amounts to -37.4m USD.
What is Eledon Pharmaceuticals Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-6%
Over the last year, the Free Cash Flow growth was 6%. The average annual Free Cash Flow growth rates for Eledon Pharmaceuticals Inc have been -9% over the past three years , -20% over the past five years , and -6% over the past ten years .
You don't have any saved screeners yet